2018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team. Here are some of our defining moments
Congress Round-Up The International Congress on in vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018. This year marks its 20th meeting, with the general theme of new approach methodologies
Retinal organoids are becoming a powerful tool in the process of drug discovery, as recently shown by researchers at Newcells Biotech and Newcastle University in a study led by Professor Majlinda Lako
Age-related macular degeneration (AMD) remains the commonest cause of blindness in the developed world. This review article by Dr Valeria Chichagova and Dr Dean Hallam provides an overview of progress made, ongoing studies and challenges ahead.
Current cell assays for in vitro screening are based on genetically modified cell lines which are crude models of human biology.
The discovery in 2007 that cells isolated from mature human tissues can be reprogrammed into cells that show pluripotency was a major breakthrough in stem cell science.
